66
Participants
Start Date
March 11, 2020
Primary Completion Date
October 24, 2022
Study Completion Date
February 15, 2023
AMG 650
AMG 650 administered orally as a tablet.
Peter MacCallum Cancer Centre, Melbourne
Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven
The Queen Elizabeth Hospital, Woodville South
Laura and Isaac Perlmutter Cancer Center at New York University Langone, New York
Roswell Park Cancer Institute, Buffalo
IRCCS Istituto Europeo di Oncologia, Milan
Wake Forest University School of Medicine, Winston-Salem
Hospital General Universitario Gregorio Marañon, Madrid
Sarah Cannon Research Institute, Nashville
Indiana University, Indianapolis
Mayo Clinic, Rochester
Stephenson Cancer Center, Oklahoma City
Texas Oncology - Baylor, Dallas
University of Texas MD Anderson Cancer Center, Houston
The Angeles Clinic and Research Institute, West Los Angeles Office, Los Angeles
Sarcoma Oncology Research Center LLC, Santa Monica
Oregon Health and Science University, Portland
Washington University, St Louis
Cross Cancer Institute, Edmonton
Princess Margaret Cancer Centre, Toronto
Aichi Cancer Center, Nagoya
National Cancer Center Hospital East, Kashiwa-shi
Collaborators (1)
Amgen
INDUSTRY
Volastra Therapeutics, Inc.
INDUSTRY